Seribantumab for Prostate Cancer

Phase-Based Progress Estimates
Prostate Cancer+20 More
Seribantumab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer treatment for patients with solid tumors that contain a specific gene fusion.

Eligible Conditions
  • Prostate Cancer
  • Esophageal Neoplasms Malignant
  • Cholangiocarcinoma
  • Sarcoma
  • Renal Cancers
  • Bile Duct Carcinoma
  • Bladder Cancer, Cancer
  • Uterine Malignancies
  • Colorectal Carcinoma
  • Solid Metastatic Tumor
  • Ovarian Cancer
  • Breast Cancer
  • Malignant Neoplasm of Pancreas
  • Head and Neck Cancer
  • Locally Advanced Solid Tumors
  • Lung Cancers
  • Cancer of the Gallbladder

Video Summary

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Up to 12 months

Up to 12 months
Objective Response Rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

Trial Design

3 Treatment Groups

Cohort 3
1 of 3
Cohort 1
1 of 3
Cohort 2
1 of 3

Experimental Treatment

75 Total Participants · 3 Treatment Groups

Primary Treatment: Seribantumab · No Placebo Group · Phase 2

Cohort 3
Experimental Group · 1 Intervention: Seribantumab · Intervention Types: Drug
Cohort 1
Experimental Group · 1 Intervention: Seribantumab · Intervention Types: Drug
Cohort 2
Experimental Group · 1 Intervention: Seribantumab · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 months

Who is running the clinical trial?

Elevation OncologyLead Sponsor
2 Previous Clinical Trials
175 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Subjects with a known history of Gilberts Disease and an isolated elevation of indirect bilirubin are eligible.
You have a disease that is responsive to standard therapy, but that has progressed or failed to respond to standard therapy.
You have at least one measurable extra-cranial lesion as defined by RECIST v1.1.
Serum AST and ALT < 2.5 × ULN, or AST and ALT < 5 × ULN if liver function abnormalities due to underlying malignancy.
ANC ≥1.5 × 109/L not requiring growth factor support for at least 7 days prior to Screening.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: November 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.